COVID-19 Vaccine Breakthrough Infections Reported to CDC — United States, January 1–April 30, 2021

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Sadoff, J., Gray, G., Vandebosch, A., Cárdenas, V., Shukarev, G., Grinsztejn, B., Goepfert, P. A., Truyers, C., Fennema, H., Spiessens, B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101544 · Cited by 2,397

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Haas, E. J., Angulo, F. J., McLaughlin, J. M., Anis, E., Singer, S. R., Khan, F., Brooks, N., Smaja, M., Mircus, G., Pan, K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00947-8 · Cited by 1,564

Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021

Thompson, M. G., Burgess, J. L., Naleway, A. L., Tyner, H. L., Yoon, S. K., Meece, J., Olsho, L. E. W., Caban-Martinez, A. J., Fowlkes, A., Lutrick, K., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7013e3 · Cited by 707

Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021

Tenforde, M. W., Olson, S. M., Self, W. H., Talbot, H. K., Lindsell, C. J., Steingrub, J. S., Shapiro, N. I., Ginde, A. A., Douin, D. J., Prekker, M. E., et al. (2021) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7018e1 · Cited by 286

The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12–15 Years — United States, May 2021

Wallace, M. M., Woodworth, K. R., Gargano, J. W., Scobie, H. M., Blain, A. E., Moulia, D., Chamberland, M. E., Reisman, N., Hadler, S. C., MacNeil, J. R., et al. (2021) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7020e1 · Cited by 141

Rapid, Sensitive, Full-Genome Sequencing of Severe Acute Respiratory Syndrome Coronavirus 2

Paden, C. R., Tao, Y., Queen, K. J., Zhang, J., Li, Y., Uehara, A., & Tong, S. (2020) · Emerging infectious diseases · doi:10.3201/eid2610.201800 · Cited by 135

Impact of the Coronavirus Disease 2019 (COVID-19) Vaccine on Asymptomatic Infection Among Patients Undergoing Preprocedural COVID-19 Molecular Screening

Tande, A. J., Pollock, B. D., Shah, N. D., Farrugia, G., Virk, A., Swift, M., Breeher, L., Binnicker, M., & Berbari, E. F. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab229 · Cited by 120

Effectiveness of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Cohort of Healthcare Personnel

Swift, M. D., Breeher, L. E., Tande, A. J., Tommaso, C. P., Hainy, C. M., Chu, H., Murad, M. H., Berbari, E. F., & Virk, A. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab361 · Cited by 98

Factors associated with SARS-CoV-2 antibody titers and prognosis of breakthrough infection in hemodialysis patients

Toda, M., Yoshifuji, A., Kikuchi, K., Koinuma, M., Komatsu, M., Fujii, K., Kato, A., Kikuchi, T., Nakazawa, A., & Ryuzaki, M. (2022) · Clinical and Experimental Nephrology · doi:10.1007/s10157-022-02188-y · Cited by 18

A Review: The Manifestations, Mechanisms, and Treatments of Musculoskeletal Pain in Patients With COVID-19

Wang, L., Yang, N., Yang, J., Zhao, S., & Su, C. (2022) · Frontiers in Pain Research · doi:10.3389/fpain.2022.826160 · Cited by 20

Update on Coronavirus 2019 Vaccine Guidelines for Transplant Recipients

Kute, V. B., Meshram, H. S., Sharma, A., Chaudhury, A. R., Sudhindran, S., Gokhale, A. G. K., Hote, M. P., Guleria, R., Rana, D. S., Prakash, J., et al. (2021) · Transplantation Proceedings · doi:10.1016/j.transproceed.2021.09.007 · Cited by 19

Breakthrough COVID-19 Infections in the US: Implications for Prolonging the Pandemic

Alcendor, D. J., Matthews-Juarez, P., Smoot, D. T., Hildreth, J. E. K., Lamar, K. D., Tabatabai, M., Wilus, D. M., & Juárez, P. D. (2022) · Vaccines · doi:10.3390/vaccines10050755 · Cited by 18

The impact of traumatic experiences, coping mechanisms, and workplace benefits on the mental health of U.S. public health workers during the COVID-19 pandemic

Koné, A., Horter, L., Rose, C. E., Rao, C. Y., Orquiola, D., Thomas, I. M., Byrkit, R., Bryant-Genevier, J., & Lopes-Cardozo, B. (2022) · Annals of Epidemiology · doi:10.1016/j.annepidem.2022.07.001 · Cited by 18

COVID-19 Vaccination Breakthrough Infections in a Real-World Setting: Using Community Reporters to Evaluate Vaccine Effectiveness

Reynolds, M. W., Xie, Y., Knuth, K. B., Mack, C. D., Brinkley, E., Toovey, S., & Dreyer, N. A. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s373183 · Cited by 18

COVID-19 severity and vaccine breakthrough infections in idiopathic inflammatory myopathies, other systemic autoimmune and inflammatory diseases, and healthy controls: a multicenter cross-sectional study from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) survey

Hoff, L. S., Ravichandran, N., Shinjo, S. K., Day, J. A., Sen, P., Júnior, J. G., Lilleker, J. B., Joshi, M. M., Agarwal, V., Kardeş, S., et al. (2022) · Rheumatology International · doi:10.1007/s00296-022-05229-7 · Cited by 19

A COVID-19 model incorporating variants, vaccination, waning immunity, and population behavior

LaJoie, Z., Usherwood, T. R., Sampath, S. G., & Srivastava, V. (2022) · Scientific Reports · doi:10.1038/s41598-022-24967-z · Cited by 20

Projecting the COVID-19 immune landscape in Japan in the presence of waning immunity and booster vaccination

Sasanami, M., Fujimoto, M., Kayano, T., Hayashi, K., & Nishiura, H. (2022) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2022.111384 · Cited by 17

Incidence and Predictors of Breakthrough and Severe Breakthrough Infections of SARS-CoV-2 After Primary Series Vaccination in Adults: A Population-Based Survey of 22 575 Participants

DeSantis, S. M., Yaseen, A. S., Hao, T., León‐Novelo, L., Talebi, Y., Valerio-Shewmaker, M. A., Pinzon-Gomez, C. L., Messiah, S. E., Kohl, H. W., Kelder, S. H., et al. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad020 · Cited by 21

Addressing the ‘hypoxia paradox’ in severe COVID-19: literature review and report of four cases treated with erythropoietin analogues

Begemann, M., Groß, O., Wincewicz, D., Hardeland, R., Gastaldi, V. D., Vieta, E., Weißenborn, K., Miskowiak, K. W., Moerer, O., & Ehrenreich, H. (2021) · Molecular Medicine · doi:10.1186/s10020-021-00381-5 · Cited by 18

Silver and Silver Nanoparticles for the Potential Treatment of COVID-19: A Review

Arjun, P. N. J., Sankar, B., Shankar, K. V., Kulkarni, N. V., Sivasankaran, S., & Shankar, B. (2022) · Coatings · doi:10.3390/coatings12111679 · Cited by 17

Vaccine against COVID-19

Picazo, J. J. (2021) · Revista Española de Quimioterapia · doi:10.37201/req/085.2021 · Cited by 22

Comorbidities and Vaccination Status of COVID-19 All-Cause Mortality at a Tertiary Care Center of Western India

Verma, M., Sharma, S., Kumar, A., Hakim, A., Bhansali, S., & Meena, R. (2022) · Cureus · doi:10.7759/cureus.21721 · Cited by 15

Profile of Brazilian inpatients with COVID-19 vaccine breakthrough infection and risk factors for unfavorable outcome

de Jesus, M. A. S., Hojo-Souza, N. S., de Moraes, T. R., Guidoni, D. L., & de Souza, F. S. H. (2022) · Revista Panamericana de Salud Pública · doi:10.26633/rpsp.2022.106 · Cited by 16

Vaccination strategies for a seasonal epidemic: a simple SIR model

Nakamura, G. M., Grammaticos, B., & Badoual, M. (2021) · Open Communications in Nonlinear Mathematical Physics · doi:10.46298/ocnmp.7463 · Cited by 15

Phase III randomized clinical trial of BV ‐4051, an Ayurvedic polyherbal formulation in moderate SARS‐CoV ‐2 infections and its impact on inflammatory biomarkers

Chitre, D., Nadkarni, S., Jagtap, N., Tulle, R., Gitte, A., Rahate, P. V., Chaskar, S., & Dey, D. (2022) · Phytotherapy Research · doi:10.1002/ptr.7683 · Cited by 16

Investigating SARS-CoV-2 breakthrough infections per variant and vaccine type

Dingemans, J., van der Veer, B. M. J. W., Gorgels, K. M. F., Hackert, V., Hensels, A. Y. J., den Heijer, C. D. J., Hoebe, C. J. P. A., Savelkoul, P. H. M., & van Alphen, L. B. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1027271 · Cited by 19

Breakthrough Symptomatic COVID-19 Infections Leading to Long Covid: Report from Long Covid Facebook Group PollPreprint

Massey, D. S., Berrent, D., & Krumholz, H. M. (2021) · medRxiv · doi:10.1101/2021.07.23.21261030 · Cited by 18

Can disposable masks be worn more than once?

Chen, H., Samet, J. M., Tong, H., Abzhanova, A., Rappold, A. G., & Prince, S. E. (2022) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2022.113908 · Cited by 15

Th2 and Th17‐associated immunopathology following SARS‐CoV‐2 breakthrough infection in Spike‐vaccinated ACE2‐humanized mice

Zhang, T., Magazine, N., McGee, M. C., Carossino, M., Veggiani, G., Kousoulas, K. G., August, A., & Huang, W. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29408 · Cited by 16

Characterization of Clinical Features of Hospitalized Patients Due to the SARS-CoV-2 Infection in the Absence of Comorbidities Regarding the Sex: An Epidemiological Study of the First Year of the Pandemic in Brazil

Sansone, N. M. S., Pereira, L. R., Boschiero, M. N., Valencise, F. E., Fraga, A. D. M. A., & Marson, F. A. L. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19158895 · Cited by 18

The effects of the COVID-19 pandemic on the mental health of workers and the associated social-economic aspects: A narrative review

Wang, H., Farokhnia, F., & Sanchuli, N. (2022) · Work · doi:10.3233/wor-220136 · Cited by 15

A Literature Survey on Vaccine Supply Chain Management Amidst COVID-19: Literature Developments, Future Directions and Open Challenges for Public Health

Joshi, S., & Sharma, M. (2022) · World · doi:10.3390/world3040049 · Cited by 15

Breakthrough SARS-CoV-2 Infections after Vaccination in North Carolina

Uschner, D., Bott, M., Santacatterina, M., Gunaratne, M., Fette, L. M., Burke, B., Strylewicz, G., Edelstein, S. L., Lagarde, W. H., MILLER, K., et al. (2022) · Vaccines · doi:10.3390/vaccines10111922 · Cited by 17

A generalized distributed delay model of COVID-19: An endemic model with immunity waning

Iyaniwura, S. A., Rabiu, M., & Kong, J. D. (2023) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2023249 · Cited by 17

Comprehensive narrative review of real-world COVID-19 vaccines: viewpoints and opportunities

Liu, S., Kang, M., Zhao, N., Zhuang, Y., Li, S., & Song, T. (2022) · Medical Review · doi:10.1515/mr-2021-0021 · Cited by 15

Clinical and genomic signatures of SARS-CoV-2 Delta breakthrough infections in New York

Duerr, R., Dimartino, D., Marier, C., Zappile, P., Levine, S., François, F., Iturrate, E., Wang, G., Dittmann, M., Lighter, J., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104141 · Cited by 14

Assessment of Simulated Surveillance Testing and Quarantine in a SARS-CoV-2–Vaccinated Population of Students on a University Campus

Motta, F. C., McGoff, K. A., Deckard, A., Wolfe, C. R., Bonsignori, M., Moody, M. A., Cavanaugh, K., Denny, T. N., Harer, J., & Haase, S. B. (2021) · JAMA Health Forum · doi:10.1001/jamahealthforum.2021.3035 · Cited by 14

Effectiveness of two coronavirus disease 2019 (COVID-19) vaccines (viral vector and inactivated viral vaccine) against severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in a cohort of healthcare workers

Marra, A. R., Miraglia, J. L., Malheiros, D. T., Guozhang, Y., Teich, V., Victor, E. D. S., Pinho, J. R. R., Cypriano, A. S., Vieira, L. W., Polonio, M., et al. (2022) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2022.50 · Cited by 14

Breakthrough SARS-CoV-2 infections in 620,000 U.S. Veterans, February 1, 2021 to August 13, 2021Preprint

Cohn, B. A., Cirillo, P. M., Murphy, C. C., Krigbaum, N. Y., & Wallace, A. W. (2021) · medRxiv · doi:10.1101/2021.10.13.21264966 · Cited by 14

COVID-19 Vaccine Hesitancy Among the Adult Population in Saudi Arabia

Rajeh, A. M. A., Daghash, H., Buanz, S. F., Altharman, H. A., & Belal, S. (2021) · Cureus · doi:10.7759/cureus.20197 · Cited by 13

When Do We Need Massive Computations to Perform Detailed COVID‐19 Simulations?

Lutz, C. B., & Giabbanelli, P. J. (2021) · Advanced Theory and Simulations · doi:10.1002/adts.202100343 · Cited by 13

Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy

Brown, R. B. (2022) · Dialogues in Health · doi:10.1016/j.dialog.2022.100074 · Cited by 11

Enhanced virulence and waning vaccine-elicited antibodies account for breakthrough infections caused by SARS-CoV-2 delta and beyond

Kwon, H., Košíková, M., Tang, W., Ortega‐Rodriguez, U., Radvák, P., Xiang, R., Mercer, K. E., Muskhelishvili, L., Davis, K., Ward, J. M., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105507 · Cited by 11

COVID-19 Breakthrough Infection Among Vaccinated Population in the United Arab Emirates

Dash, N. R., Barqawi, H. J., Obaideen, A. A., Chame, H. Q. A., Samara, K. A., Qadri, R., & Eldesouki, S. (2023) · Journal of Epidemiology and Global Health · doi:10.1007/s44197-023-00090-8 · Cited by 12

Safety and Immunogenicity Following the Second and Third Doses of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents with Juvenile-Onset Autoimmune Inflammatory Rheumatic Diseases: A Prospective Multicentre Study

Heshin‐Bekenstein, M., Ziv, A., Toplak, N., Lazauskas, S., Kadishevich, D., Yaari, E. B.-N., Miller‐Barmak, A., Aviel, Y. B., Saiag, E., Pel, S., et al. (2023) · Vaccines · doi:10.3390/vaccines11040819 · Cited by 12

Clinical Outcomes of Adult Patients Hospitalized with COVID-19 after Vaccination

Kalligeros, M., Shehadeh, F., Mylona, E. K., Kaczynski, M., Kalagara, S., Atalla, E., Tsikala-Vafea, M., & Mylonakis, E. E. (2021) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed6040175 · Cited by 13

COVID Vaccination in Athletes and Updated Interim Guidance on the Preparticipation Physical Examination During the SARS-Cov-2 Pandemic

Narducci, D. M., Diamond, A. B., Bernhardt, D. T., & Roberts, W. O. (2021) · Clinical Journal of Sport Medicine · doi:10.1097/jsm.0000000000000981 · Cited by 12

Interleukin-1 Inhibitors and Vaccination Including COVID-19 in Inflammatory Rheumatic Diseases: A Nonsystematic Review

Atagündüz, P., Keser, G., & Soy, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.734279 · Cited by 14

Adults hospitalized with breakthrough COVID‐19 have lower mortality than matched unvaccinated adults

Myers, L. C., Kipnis, P., Greene, J., Lawson, B. L., Escobar, G. J., FIREMAN, B. H., Klein, N. P., & Liu, V. X. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13504 · Cited by 13

Assessment of Clinical Profile and Treatment Outcome in Vaccinated and Unvaccinated SARS-CoV-2 Infected Patients

Korishettar, G., Chikkahonnaiah, P., Tulimilli, S. V., Dallavalasa, S., Byrappa, S. H., Madhunapantula, S. V., & Veeranna, R. P. (2022) · Vaccines · doi:10.3390/vaccines10071125 · Cited by 12

Adaptive immune responses in vaccinated patients with symptomatic SARS-CoV-2 Alpha infection

Park, H.-S., Shapiro, J. R., Sitaras, I., Woldemeskel, B. A., Garliss, C. C., Dziedzic, A., Sachithanandham, J., Jedlicka, A., Caputo, C. A., Rousseau, K. E., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.155944 · Cited by 10

Incidence and severity of COVID-19 infection post-vaccination: a survey among Indian doctors

Parameswaran, A., Apsingi, S., Eachempati, K. K., Dannana, C. S., Jagathkar, G. M., Iyer, M., & Aribandi, H. (2022) · Infection · doi:10.1007/s15010-022-01758-2 · Cited by 13

Association of mortality and early tracheostomy in patients with COVID-19: a retrospective analysis

Flinspach, A., Booke, H., Zacharowski, K., Balaban, Ü., Herrmann, E., & Adam, E. (2022) · Scientific Reports · doi:10.1038/s41598-022-19567-w · Cited by 11

Mathematical model of COVID-19 transmission dynamics incorporating booster vaccine program and environmental contamination

Akinwande, N., Ashezua, T. T., Gweryina, R. I., Somma, S. A., Oguntolu, F. A., Usman, A., Abdurrahman, N. O., Kaduna, F. S., Adajime, T. P., Kuta, F. A., et al. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e11513 · Cited by 11

What is always necessary throughout efforts to prevent and control COVID-19 and other infectious diseases? A physical containment strategy and public mobilization and management

Luo, M., Sun, J., Gong, Z., & Wang, Z. (2021) · BioScience Trends · doi:10.5582/bst.2021.01218 · Cited by 11

B cell receptor signatures associated with strong and poor SARS-CoV-2 vaccine responses

Lin, K., Zhou, Y., Ai, J., Wang, Y. A., Zhang, S., Qiu, C., Lian, C., Gao, B., Liu, T., Wang, H., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2030197 · Cited by 11

Panorama of Breakthrough Infection Caused by SARS-CoV-2: A Review

Fan, Q., Nie, Z., & Xie, S. (2022) · Medicina · doi:10.3390/medicina58121733 · Cited by 10

Trends and Correlates of Breakthrough Infections With SARS-CoV-2

Yamal, J., Appana, S. N., Wang, M., León‐Novelo, L., Bakota, E. V., Ye, Y., Sharma, S. V., Morrison, A. C., Marko, D., Linder, S. H., et al. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.856532 · Cited by 10

Humoral Responses Elicited after a Fifth Dose of SARS-CoV-2 mRNA Bivalent Vaccine

Tauzin, A., Beaudoin-Bussières, G., Benlarbi, M., Nayrac, M., Bo, Y., Gendron‐Lepage, G., Medjahed, H., Perreault, J., Gokool, L., Arlotto, P., et al. (2023) · Viruses · doi:10.3390/v15091926 · Cited by 10

COVID-19 breakthrough infections among people living with and without HIV: A statewide cohort analysis

Yang, X., Zhang, J., Liu, Z., Chen, S., Olatosi, B., Poland, G. A., Weissman, S., & Li, X. (2023) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2023.11.029 · Cited by 10

Antibodies, boosters, and optimizing SARS-CoV-2 vaccines for transplantation: A call for more research

Ison, M. G., Blumberg, E. A., Halasa, N., Kaul, D. R., Theodoropoulos, N. M., & Wolfe, C. R. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16758 · Cited by 10

Should Breakthrough SARS-CoV-2 Infection Affect Our Confidence in the COVID-19 Vaccines?

Lamptey, E. (2021) · Infection and Chemotherapy · doi:10.3947/ic.2021.0134 · Cited by 10

Human Identical Sequences, hyaluronan, and hymecromone ─ the new mechanism and management of COVID-19

Yang, S., Tong, Y., Chen, L., & Yu, W. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00077-0 · Cited by 10

Fully understanding the efficacy profile of the COVID-19 vaccination and its associated factors in multiple real-world settings

Panahi, Y., Einollahi, B., Beiraghdar, F., Darvishi, M., Fathi, S., Javanbakht, M., Shafiee, S., & Akhavan‐Sigari, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.947602 · Cited by 10

Effectiveness of four vaccines in preventing SARS-CoV-2 infection in Almaty, Kazakhstan in 2021: retrospective population-based cohort study

Nabirova, D., Horth, R., Smagul, M., Nukenova, G., Yesmagambetova, A., Singer, D. A., Henderson, A. K., & Tsoy, A. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1205159 · Cited by 11

A Delay Differential Equation approach to model the COVID-19 pandemicPreprint

Kiselev, I. N., Akberdin, I. R., & Kolpakov, F. (2021) · medRxiv · doi:10.1101/2021.09.01.21263002 · Cited by 10

Emerging SARS-CoV-2 variants: genomic shifts, immune evasion, and therapeutic perspectives

Wehbe, R., Khoshman, N., Ousseily, Z., Al-Tameemi, S. A., Majzoub, R. E., Najar, M., Merimi, M., Fayyad‐Kazan, H., Badran, B. M., & Fayyad‐Kazan, M. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-11009-w · Cited by 9

Virological and Serological Characterisation of SARS-CoV-2 Infections Diagnosed After mRNA BNT162b2 Vaccination Between December 2020 and March 2021

Colavita, F., Meschi, S., Gruber, C. E. M., Rueca, M., Vairo, F., Matusali, G., Lapa, D., Giombini, E., Carli, G. D., Spaziante, M., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.815870 · Cited by 9

Low‐frequency variants in mildly symptomatic vaccine breakthrough infections presents a doubled‐edged sword

Magalis, B. R., Mavian, C. N., Tagliamonte, M. S., Rich, S. N., Cash, M. N., Riva, A., Loeb, J. C., Norris, M. H., Amador, D. M., Zhang, Y., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27726 · Cited by 9

COVID-19 vaccine effectiveness among people living with and without HIV in South Carolina, USA: protocol of a population-based cohort study

Yang, X., Zhang, J., Olatosi, B., Weissman, S., & Li, X. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-067095 · Cited by 9

Role of vaccination and anti-SARS-CoV-2 antibodies in the clinical outcome of hospitalized COVID-19 patients

Bernal, E., García-Villalba, E., Pons, E., Vicente, M. R., Tomás, C., Minguela, A., Hernández, M. D., Puche, G., Carter, P., Martínez, M. M., et al. (2023) · Medicina Clínica · doi:10.1016/j.medcli.2022.12.018 · Cited by 8

In‐vitro antiviral screening of some thiopyranothiazoles

Kryshchyshyn‐Dylevych, A., Kaminskyy, D. V., & Lesyk, R. (2023) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2023.110738 · Cited by 9

Statistical estimation of deltoid subcutaneous fat pad thickness: implications for needle length for vaccination

Sebro, R. (2022) · Scientific Reports · doi:10.1038/s41598-022-05020-5 · Cited by 9

Clinical characterization of COVID-19 breakthrough infections, Philippines

Velasco, J. M., Vila, V., Diones, P. C., Valderama, M. T., Mendez, C., Turao-Agoncillo, M. M. M., Chinnawirotpisan, P., Manasatienkij, W., Joonlasak, K., Klungthong, C., et al. (2022) · Journal of Clinical Virology · doi:10.1016/j.jcv.2022.105157 · Cited by 9

Modeling the Influence of Vaccine Administration on COVID-19 Testing Strategies

Forde, J. E., & Ciupe, S. M. (2021) · Viruses · doi:10.3390/v13122546 · Cited by 9

What is the Hidden Biological Mechanism Underlying the Possible SARS-CoV-2 Vertical Transmission? A Mini Review

Sessa, R., Anastasi, E., Brandolino, G., Brunelli, R., Pietro, M. D., Filardo, S., Masciullo, L., Terrin, G., Viscardi, M. F., & Porpora, M. G. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.875806 · Cited by 9

No correlation of neutralizing antibody titers against the Omicron variant after a booster dose of COVID-19 vaccines with subsequent breakthrough Omicron infections among healthcare workers

Lee, J., Park, S., Kim, J. Y., Lim, S. Y., Chang, E., Bae, S., Jung, J., Kim, M. J., Chong, Y. P., Lee, S., et al. (2022) · Journal of Infection · doi:10.1016/j.jinf.2022.10.007 · Cited by 10

Antibody Response after SARS-CoV-2 Infection with the Delta and Omicron Variant

Błaszczuk, A., Michalski, A., Sikora, D., Malm, M., Drop, B., & Polz‐Dacewicz, M. (2022) · Vaccines · doi:10.3390/vaccines10101728 · Cited by 9

Cost-Effectiveness of the Second COVID-19 Booster Vaccination in the USA

Li, R., Lu, P., Fairley, C. K., Pagán, J. A., Hu, W., Yang, Q., Zhuang, G., Shen, M., Li, Y., & Zhang, L. (2023) · Applied Health Economics and Health Policy · doi:10.1007/s40258-023-00844-2 · Cited by 8

Mental health conditions and COVID-19 vaccine outcomes: A scoping review

Jia, R., Coupland, C. A. C., Vinogradova, Y., Qureshi, N., Turner, E. L., & Vedhara, K. (2024) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2024.111826 · Cited by 8

SARS-CoV-2 Vaccination and Protection Against Clinical Disease: A Retrospective Study, Bouches-du-Rhône District, Southern France, 2021

Fournier, P., Houhamdi, L., Colson, P., Cortaredona, S., Delorme, L., Cassagne, C., Lagier, J., Chaudet, H., Tissot‐Dupont, H., Giraud‐Gatineau, A., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.796807 · Cited by 8

Rate of True-Positive Findings of COVID-19 Typical Appearance at Chest CT per RSNA Consensus Guidelines in an Increasingly Vaccinated Population

Polyakov, N. J., Som, A., Mercaldo, N. D., Capua, J. D., Little, B. P., & Flores, E. J. (2022) · Radiology · doi:10.1148/radiol.220680 · Cited by 8

The Effect of a Booster Dose mRNA Vaccine on COVID-19 Infection in Kidney Transplant Recipients after Inactivated or Viral Vector Vaccine Immunization

Thotsiri, S., Sittiudomsuk, R., Sutharattanapong, N., Kantachuvesiri, S., & Wiwattanathum, P. (2022) · Vaccines · doi:10.3390/vaccines10101690 · Cited by 9

Understanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfection

Al-Hatamleh, M. A. I., Abusalah, M. A. H., Hatmal, M. M., Alshaer, W., Ahmad, S., Mohd-Zahid, M. H., Rahman, E. N. S. E. A., Yean, C. Y., Alias, I. Z., Uskoković, V., et al. (2022) · Journal of Taibah University Medical Sciences · doi:10.1016/j.jtumed.2022.11.007 · Cited by 8

Using the theory of planned behavior to assess willingness and attitudes towards COVID-19 vaccination among a predominantly white U.S. college sample

Reyes, C. T., Cao, W., Astorini, A. G., Drohan, M. M., Schulz, C. T., Shuster, C. L., Robbins, M. L., Yang, M., & Stamates, A. L. (2023) · Health Psychology and Behavioral Medicine · doi:10.1080/21642850.2023.2248236 · Cited by 8

The rates and symptoms of natural and breakthrough infection pre- and post- Covid-19 non-mRNA vaccination at various peaks amongst Iranian healthcare workers

Jamalidoust, M., Eilami, O., Ashkan, Z., Ziyaeyan, M., Aliabadi, N., & Habibi, M. (2023) · Virology Journal · doi:10.1186/s12985-023-02156-2 · Cited by 7

Impact of COVID-19 on healthcare waste generation: Correlations and trends from a tertiary hospital of a developed country

Garlasco, J., Canepari, A., Giacobone, G., Funicelli, G., Kozel, D., Bernini, L., & Cotroneo, A. (2022) · Waste Management & Research The Journal for a Sustainable Circular Economy · doi:10.1177/0734242x221074195 · Cited by 8

Synthesis and Biochemical Evaluation of 8H-Indeno[1,2-d]thiazole Derivatives as Novel SARS-CoV-2 3CL Protease Inhibitors

Wu, J., Feng, B., Gao, L., Zhang, C., Li, J. X., Xiang, D.-J., Zang, Y., & Wang, W.-L. (2022) · Molecules · doi:10.3390/molecules27103359 · Cited by 8

Parents' perception of COVID-19 risk of infection and intention to vaccinate their children

Sabra, H. K., Bakr, M. A., Rageh, O. E. S. M., Khaled, A., Elbakliesh, O. M., & Kabbash, I. (2022) · Vacunas (English Edition) · doi:10.1016/j.vacun.2022.07.004 · Cited by 7

Modified susceptible–exposed–infectious–recovered model for assessing the effectiveness of non-pharmaceutical interventions during the COVID-19 pandemic in Seoul

Jung, S., Kim, J., Hwang, S.-S., Choi, J., & Lee, W. (2022) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2022.111329 · Cited by 9

An Overview of Current Accomplishments and Gaps of COVID-19 Vaccine Platforms and Considerations for Next Generation Vaccines

Kale, A., Gaur, A., Menon, I., Chirmule, N. B., Bagwe, P., Jawa, R., Vijayanand, S., Patil, S., Suresh, S., & Jawa, V. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.01.019 · Cited by 8

Postvaccination SARS-COV-2 among Health Care Workers in New Jersey: A Genomic Epidemiological Study

Mathema, B., Chen, L., Chow, K. F., Zhao, Y., Zody, M. C., Mediavilla, J. R., Cunningham, M. H., Composto, K., Lee, A., Oschwald, D. M., et al. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.01882-21 · Cited by 7

COVID-19 breakthrough infections in vaccinated individuals at BPKIHS, Nepal

Karmacharya, A., Rai, K., Siwakoti, S., Khanal, B., & Bhattarai, N. R. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-09902-z · Cited by 7

A Potent Recombinant Polyclonal Antibody Therapeutic for Protection Against New Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern

Wayham, N. P., Niedecken, A. R., Simons, J. F., Chiang, Y., Medina‐Cucurella, A. V., Mizrahi, R. A., Wagner, E. K., Gras, A., Segal, I., Witte, P., et al. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad102 · Cited by 7

Surveillance genome sequencing reveals multiple SARS‐CoV‐2 variants circulating in central Texas, USA, with a predominance of delta variant and review of vaccine breakthrough cases

Mutnal, M. B., Johnson, S., Mohamed, N., Abddelgader, R., Morales, L., Volz, M., Walker, K., Arroliga, A. C., & Rao, A. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27373 · Cited by 7

COVID-19 vaccination and breakthrough infections among healthcare workers: an online survey

Masthi, N. R. R., & Hebbar, G. (2021) · International Journal of Community Medicine and Public Health · doi:10.18203/2394-6040.ijcmph20214284 · Cited by 7

The short-term effectiveness of coronavirus disease 2019 (COVID-19) vaccines among healthcare workers: a systematic literature review and meta-analysis

Marra, A. R., Kobayashi, T., Suzuki, H., Alsuhaibani, M., Tofaneto, B. M., Bariani, L. M., Auler, M. D. A., Salinas, J. L., Edmond, M. B., Pinho, J. R. R., et al. (2021) · Antimicrobial Stewardship & Healthcare Epidemiology · doi:10.1017/ash.2021.195 · Cited by 7

COVID Vaccination in Athletes & Updated Interim Guidance on the Preparticipation Physical Examination during the SARS-CoV-2 Pandemic

Narducci, D. M., Diamond, A. B., Bernhardt, D. T., & Roberts, W. O. (2021) · Current Sports Medicine Reports · doi:10.1249/jsr.0000000000000912 · Cited by 7

Severe Acute Respiratory Syndrome Coronavirus 2 Delta Vaccine Breakthrough Transmissibility in Alachua County, Florida

Magalis, B. R., Rich, S. N., Tagliamonte, M. S., Mavian, C. N., Cash, M. N., Riva, A., Marini, S., Amador, D. M., Zhang, Y., Shapiro, J., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac197 · Cited by 7

Modeling COVID-19 transmission between age groups in the United States considering virus mutations, vaccinations, and reinfection

Roy, J., Heath, S. M., Wang, S., & Ramkrishna, D. (2022) · Scientific Reports · doi:10.1038/s41598-022-21559-9 · Cited by 7

Association between breakthrough infection with COVID-19 and Toxoplasma gondii: a cross-sectional study

Gouda, M. A., AboShabaan, H. S., Abdelgawad, A. S., Wahed, A. S. A., El‐Razik, K. A. A., Elsaadawy, Y., Abdel-Wahab, A., & Hawash, Y. A. (2023) · Scientific Reports · doi:10.1038/s41598-023-44616-3 · Cited by 7

COVID-19 vaccines & pandemic

Bhatia, R., & Abraham, P. (2021) · The Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_1821_21 · Cited by 7

Does vaccination elicit risk compensation? Insights from the COVID-19 pandemic in France

McColl, K., Martin-Lapoirie, D., Veltri, G., Arwidson, P., & Raude, J. (2023) · Health Psychology and Behavioral Medicine · doi:10.1080/21642850.2023.2287663 · Cited by 6

Path analysis of perceived disease vulnerability, COVID-19 fear, and lower vaccine hesitancy within the context of protection motivation theory

Bok, S., Shum, J., & Lee, M. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e25889 · Cited by 6

Trust Us—We Are the (COVID-19 Misinformation) Experts: A Critical Scoping Review of Expert Meanings of “Misinformation” in the Covid Era

Chaufan, C., Hemsing, N., Heredia, C., & McDonald, J. L. (2024) · COVID · doi:10.3390/covid4090101 · Cited by 6

A guided twin delayed deep deterministic reinforcement learning for vaccine allocation in human contact networks

Ardjmand, E., Fallahtafti, A., Yazdani, E., Mahmoodi, A., & Young, W. A. (2024) · Applied Soft Computing · doi:10.1016/j.asoc.2024.112322 · Cited by 6

In-depth Characterization of Vaccine Breakthrough Infections With SARS-CoV-2 Among Health Care Workers in a Dutch Academic Medical Center

Rümke, L. W., Groenveld, F. C., van Os, Y. M. G., Praest, P., Tanja, A. A. N., de Jong, D. C. M., Symons, J., Schuurman, R., Reinders, T., Hofstra, L. M., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab553 · Cited by 6

Worker Response to the Rapid Changes Caused by Disruptive Innovation

Brown, B. A., & Heitner, K. L. (2022) · Advances in human resources management and organizational development book series · doi:10.4018/978-1-7998-8827-7.ch011 · Cited by 6

Estimating the number of symptomatic SARS-CoV-2 infections among vaccinated individuals in the United States—January–July, 2021

Kugeler, K. J., Williamson, J., Curns, A. T., Healy, J. M., Nolen, L. D., Clark, T. A., Martin, S. W., & Fischer, M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0264179

Editorial: SARS-CoV-2 Vaccine Responses and Breakthrough COVID-19

Parums, D. V. (2021) · Medical Science Monitor · doi:10.12659/msm.935624 · Cited by 4

COVID-19 Vaccination Breakthrough Infections in a Real-World Setting: Using Community Reporters to Evaluate Vaccine Effectiveness

Reynolds, M. W., Xie, Y., Knuth, K. B., Mack, C. D., Brinkley, E., Toovey, S., & Dreyer, N. A. (2022) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 1

The impact of vaccination on COVID-19

Shamama, F., Zhamutashvili, M., Dolmazashvili, E., Badridze, N., Gognadze, T., & Sharvadze, L. (2023) · Journal of Biomedical and Medical Sciences · doi:10.51231/2667-9507-2023-002-01-62-66 · Cited by 1

POSC419 Examining the Rate of COVID-19 Breakthrough Infections in Individuals Who Received mRNA Vaccine in the United States

Madge, V. J., Bhardwaj, N., & Mazumder, D. (2022) · Value in Health · doi:10.1016/j.jval.2021.11.1320